Cabozantinib Offers New Option for Rare Neuroendocrine Tumors
The FDA has approved the multi-kinase inhibitor cabozantinib for certain adult and pediatric patients with rare neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for patients 12 years and...